Prothrombin G20210A: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Prothrombin G20210A | |||
| image = [[File:Classical_blood_coagulation_pathway.png|250px]] | |||
| caption = Classical blood coagulation pathway | |||
| field = [[Hematology]] | |||
| synonyms = Factor II mutation, Prothrombin 20210 mutation | |||
| symptoms = Increased risk of [[venous thromboembolism]], [[deep vein thrombosis]], [[pulmonary embolism]] | |||
| complications = [[Thrombosis]], [[stroke]], [[myocardial infarction]] | |||
| onset = Varies, often diagnosed in young adults | |||
| duration = Lifelong | |||
| causes = Genetic mutation in the [[F2 gene]] | |||
| risks = Family history, [[oral contraceptive]] use, [[pregnancy]], [[hormone replacement therapy]] | |||
| diagnosis = [[Genetic testing]], [[DNA analysis]] | |||
| differential = [[Factor V Leiden]], [[antithrombin deficiency]], [[protein C deficiency]], [[protein S deficiency]] | |||
| prevention = Risk factor management, [[anticoagulation therapy]] | |||
| treatment = [[Anticoagulant]] medications, lifestyle modifications | |||
| prognosis = Generally good with management, increased risk of thrombotic events | |||
| frequency = 1-2% of the general population | |||
| deaths = Rare, related to complications of thrombosis | |||
}} | |||
'''Prothrombin G20210A''' is a genetic condition that increases the risk of developing abnormal blood clots in veins, a condition known as venous thromboembolism. This condition is caused by a specific mutation in the F2 gene, which provides instructions for making a protein called prothrombin (also known as coagulation factor II). | '''Prothrombin G20210A''' is a genetic condition that increases the risk of developing abnormal blood clots in veins, a condition known as venous thromboembolism. This condition is caused by a specific mutation in the F2 gene, which provides instructions for making a protein called prothrombin (also known as coagulation factor II). | ||
==Causes== | ==Causes== | ||
The [[F2 gene]] mutation that causes Prothrombin G20210A results in the production of an abnormally high amount of prothrombin. This excess prothrombin increases the risk of developing abnormal blood clots in veins, a condition known as venous thromboembolism. | The [[F2 gene]] mutation that causes Prothrombin G20210A results in the production of an abnormally high amount of prothrombin. This excess prothrombin increases the risk of developing abnormal blood clots in veins, a condition known as venous thromboembolism. | ||
==Symptoms== | ==Symptoms== | ||
People with Prothrombin G20210A may not have any signs or symptoms unless they develop abnormal blood clots. These clots can cause symptoms such as pain, swelling, warmth and redness in the affected area. If the clot is in the lungs (pulmonary embolism), it can cause shortness of breath, chest pain and coughing up blood. | People with Prothrombin G20210A may not have any signs or symptoms unless they develop abnormal blood clots. These clots can cause symptoms such as pain, swelling, warmth and redness in the affected area. If the clot is in the lungs (pulmonary embolism), it can cause shortness of breath, chest pain and coughing up blood. | ||
==Diagnosis== | ==Diagnosis== | ||
Prothrombin G20210A is diagnosed through genetic testing, which can identify the mutation in the F2 gene. This test is usually done if a person has a personal or family history of abnormal blood clots. | Prothrombin G20210A is diagnosed through genetic testing, which can identify the mutation in the F2 gene. This test is usually done if a person has a personal or family history of abnormal blood clots. | ||
==Treatment== | ==Treatment== | ||
Treatment for Prothrombin G20210A typically involves medications to prevent or treat blood clots. These may include anticoagulant medications, which prevent blood clots from forming, and thrombolytic medications, which break up existing clots. | Treatment for Prothrombin G20210A typically involves medications to prevent or treat blood clots. These may include anticoagulant medications, which prevent blood clots from forming, and thrombolytic medications, which break up existing clots. | ||
==See Also== | ==See Also== | ||
* [[Venous thromboembolism]] | * [[Venous thromboembolism]] | ||
| Line 19: | Line 35: | ||
* [[Anticoagulant medications]] | * [[Anticoagulant medications]] | ||
* [[Thrombolytic medications]] | * [[Thrombolytic medications]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Blood disorders]] | [[Category:Blood disorders]] | ||
[[Category:Coagulation, bleeding and clotting disorders]] | [[Category:Coagulation, bleeding and clotting disorders]] | ||
{{stub}} | {{stub}} | ||
Latest revision as of 05:25, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Prothrombin G20210A | |
|---|---|
| File:Classical blood coagulation pathway.png | |
| Synonyms | Factor II mutation, Prothrombin 20210 mutation |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Increased risk of venous thromboembolism, deep vein thrombosis, pulmonary embolism |
| Complications | Thrombosis, stroke, myocardial infarction |
| Onset | Varies, often diagnosed in young adults |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation in the F2 gene |
| Risks | Family history, oral contraceptive use, pregnancy, hormone replacement therapy |
| Diagnosis | Genetic testing, DNA analysis |
| Differential diagnosis | Factor V Leiden, antithrombin deficiency, protein C deficiency, protein S deficiency |
| Prevention | Risk factor management, anticoagulation therapy |
| Treatment | Anticoagulant medications, lifestyle modifications |
| Medication | N/A |
| Prognosis | Generally good with management, increased risk of thrombotic events |
| Frequency | 1-2% of the general population |
| Deaths | Rare, related to complications of thrombosis |
Prothrombin G20210A is a genetic condition that increases the risk of developing abnormal blood clots in veins, a condition known as venous thromboembolism. This condition is caused by a specific mutation in the F2 gene, which provides instructions for making a protein called prothrombin (also known as coagulation factor II).
Causes[edit]
The F2 gene mutation that causes Prothrombin G20210A results in the production of an abnormally high amount of prothrombin. This excess prothrombin increases the risk of developing abnormal blood clots in veins, a condition known as venous thromboembolism.
Symptoms[edit]
People with Prothrombin G20210A may not have any signs or symptoms unless they develop abnormal blood clots. These clots can cause symptoms such as pain, swelling, warmth and redness in the affected area. If the clot is in the lungs (pulmonary embolism), it can cause shortness of breath, chest pain and coughing up blood.
Diagnosis[edit]
Prothrombin G20210A is diagnosed through genetic testing, which can identify the mutation in the F2 gene. This test is usually done if a person has a personal or family history of abnormal blood clots.
Treatment[edit]
Treatment for Prothrombin G20210A typically involves medications to prevent or treat blood clots. These may include anticoagulant medications, which prevent blood clots from forming, and thrombolytic medications, which break up existing clots.
